29.07 10:15 | dpa-AFX: Biotech Stocks Facing FDA Decision In August 2024 |
10.07 09:53 | dpa-AFX: *BARCLAYS HEBT ZIEL FÜR REGENERON PHARMA AUF 1200 (1050) USD - 'OVERWEIGHT' |
10.07 09:53 | dpa-AFX: *BARCLAYS RAISES REGENERON PHARMA PRICE TARGET TO 1200 (1050) USD - 'OVERWEIGHT' |
08.07 14:05 | dpa-AFX: Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge |
08.07 13:58 | dpa-AFX: *REGENERON ANTICIPATES $24 MLN R&D CHARGE IN Q2 RESULTS |
03.07 08:15 | dpa-AFX: Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
03.07 08:15 | Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
03.07 08:10 | dpa-AFX: Sanofi-Blockbuster Dupixent: Zulassung in Europa für spezielle Lungenkrankheit |
03.07 07:39 | Sanofi erhält EU-Zulassung für Dupixent als COPD-Therapie |
03.07 07:31 | dpa-AFX: Regeneron, Sanofi: EU Approves Dupixent As First-ever Targeted Therapy For COPD Patients |
03.07 07:11 | dpa-AFX: *REGENERON: EC APPROVES DUPIXENT AS ADD-ON MAINTENANCE TREATMENT FOR ADULTS WITH COPD |
28.06 13:20 | dpa-AFX: Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU |
28.06 13:11 | dpa-AFX: *REGENERON: ODRONEXTAMAB RECOMMENDED FOR EU APPROVAL BY CHMP TO TREAT R/R FOLLICULAR LYMPHOMA AND DLBCL |
11.06 13:51 | dpa-AFX: Regeneron, Sanofi Report FDA Approval Of Kevzara To Treat Active PJIA |
11.06 13:04 | dpa-AFX: *REGENERON AND SANOFI: FDA APPROVES KEVZARA FOR TREATMENT OF ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS |
04.06 15:31 | dpa-AFX: *FIBROGEN +15% - VEREINBARUNG MIT REGENERON ÜBER KLINISCHE STUDIEN |
04.06 13:18 | dpa-AFX: *FIBROGEN VORBÖRSLICH +15% - VEREINBARUNG MIT REGENERON ÜBER KLINISCHE STUDIEN |
31.05 08:10 | US-Prüfung für Sanofi-Arznei Dupixent um drei Monate verlängert |
31.05 07:29 | dpa-AFX: Sanofi, Regeneron: Dupixent Recommended For EU Approval By CHMP To Treat COPD Patients |
31.05 07:19 | dpa-AFX: Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month |
|